SAB Biotherapeutics Inc (SABS) — Cash Flow Quality Index
SAB Biotherapeutics Inc (SABS) has a Cash Flow Quality Index of -2.44x as of September 2025. Operating cash flow of $-13.05 Million is below net income of $5.34 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore how much of SAB Biotherapeutics Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
SAB Biotherapeutics Inc Cash Flow Quality Index (2020–2025)
Historical Cash Flow Quality Index for SAB Biotherapeutics Inc across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check SABS tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for SAB Biotherapeutics Inc (2020–2025)
Year-by-year earnings quality comparison for SAB Biotherapeutics Inc. For live market cap and the full company financial profile, see SAB Biotherapeutics Inc market capitalisation.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -3.37x | $-44.78 Million | $13.27 Million | ▼ -778.3% |
| 2020 | 0.50x | $10.00 Million | $20.12 Million | — |